ESMO 2022 Highlights

CME

Key Studies in Breast, Gynecologic, Renal Cell, Urothelial, Lung, Hepatobiliary, and Skin Cancers: CCO Independent Conference Highlights of the 2022 ESMO Congress

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: November 14, 2022

Expiration: November 13, 2023

Nicoletta Colombo
Nicoletta Colombo, MD, PhD
Robert Motzer
Robert Motzer, MD
Sapna P. Patel
Sapna P. Patel, MD
David Planchard
David Planchard, MD, PhD
Elizabeth Plimack
Elizabeth Plimack, MD, MS
Rachna Shroff
Rachna Shroff, MD, MS
Sara M. Tolaney
Sara M. Tolaney, MD, MPH

Pretest

Progress
1 2
Course Completed
1.
Which of the following findings was reported from the TROPiCS-02 trial for sacituzumab govitecan when compared with physician's choice of chemotherapy in patients with hormone receptor–positive/HER2-negative breast cancer?